Edition:
India

Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

26.59USD
19 Feb 2019
Change (% chg)

-- (--)
Prev Close
$26.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
207,038
52-wk High
$39.50
52-wk Low
$6.78

Latest Key Developments (Source: Significant Developments)

Evolus Receives FDA Approval For Jeuveau Prabotulinumtoxina-XVFS For Injection
Saturday, 2 Feb 2019 

Feb 1 (Reuters) - Evolus Inc ::EVOLUS RECEIVES FDA APPROVAL FOR JEUVEAU™ PRABOTULINUMTOXINA-XVFS FOR INJECTION.EVOLUS INC - JEUVEAU LAUNCH PLANNED IN SPRING 2019.EVOLUS INC - JEUVEAU MAY CAUSE SERIOUS SIDE EFFECTS THAT CAN BE LIFE THREATENING.EVOLUS INC - JEUVEAU MAY CAUSE SERIOUS SIDE EFFECTS SUCHS AS PROBLEMS SWALLOWING, SPEAKING, OR BREATHING AND SPREAD OF TOXIN EFFECTS.  Full Article

Evolus Receives Conditional FDA Acceptance Of Jeuveau Brand Name
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Evolus Inc ::EVOLUS RECEIVES CONDITIONAL FDA ACCEPTANCE OF JEUVEAU BRAND NAME.EVOLUS INC - IN COMING MONTHS, EVOLUS PLANS TO ACCELERATE ITS TRANSITION FROM AN RESEARCH AND DEVELOPMENT TO A COMMERCIAL STAGE COMPANY.  Full Article

Evolus Receives Acceptance Of FDA BLA Resubmission For Dwp-450
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Evolus Inc ::EVOLUS RECEIVES ACCEPTANCE OF FDA BLA RESUBMISSION FOR DWP-450.EVOLUS INC - FDA CONSIDERED RESUBMISSION A CLASS 2 RESPONSE AND HAS ASSIGNED A FEBRUARY 2, 2019 ACTION DATE PER PRESCRIPTION DRUG USER FEE ACT.  Full Article

Evolus Announces Update With DWP-450 Regulatory Submissions
Wednesday, 16 May 2018 

May 16 (Reuters) - Evolus Inc ::EVOLUS ANNOUNCES PROGRESS WITH DWP-450 REGULATORY SUBMISSIONS.EVOLUS INC - CONFERENCE CALL SCHEDULED FOR 8:30AM ET / 5:30AM PT.EVOLUS INC - EVOLUS RECEIVES FDA COMPLETE RESPONSE LETTER WITH COMMENTS ISOLATED TO CMC ITEMS.EVOLUS INC - PLANS TO UTILIZE DAEWOONG FACILITY TO SUPPORT COMMERCIAL PRODUCTION FOLLOWING ANTICIPATED APPROVAL OF DWP-450..EVOLUS INC - FDA ISSUES FAVORABLE EIR LETTER RELATED TO MANUFACTURING FACILITY.EVOLUS INC - DWP-450 MANUFACTURING FACILITY IS FULLY VALIDATED BY DAEWOONG UNDER CURRENT GOOD MANUFACTURING PRACTICE REQUIREMENTS.EVOLUS INC - IN CRL, DEFICIENCIES CITED BY FDA WERE ISOLATED TO ITEMS RELATED TO CHEMISTRY, MANUFACTURING, AND CONTROLS PROCESSES.EVOLUS INC - EXPECTS TO RESPOND TO FDA ABOUT CRL WITH A COMPLETE SUBMISSION TO FDA WITHIN 90 DAYS.EVOLUS INC - LOOK FORWARD TO WORKING CLOSELY WITH FDA AND REMAIN COMMITTED TO BRINGING DWP-450 TO MARKET BY SPRING 2019.EVOLUS INC - DWP-450 MANUFACTURING FACILITY HAS CAPACITY EXPECTED TO MEET ANTICIPATED PRODUCT DEMAND.  Full Article

Evolus Reports Q1 Loss Per Share $0.30
Friday, 11 May 2018 

May 10 (Reuters) - Evolus Inc ::EVOLUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.30.Q1 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.  Full Article

Evolus Appoints Allergan Aesthetics Head As President And Chief Executive Officer
Monday, 7 May 2018 

May 7 (Reuters) - Evolus Inc ::EVOLUS APPOINTS ALLERGAN AESTHETICS HEAD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.SAYS DAVID MOATAZEDI APPOINTED CEO AND PRESIDENT.MOATAZEDI WILL SUCCEED MURTHY SIMHAMBHATLA.  Full Article

Photo

FDA approves cheaper Botox rival to treat frown lines

(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7)